ERBB2 and breast cancer: For example, the 21‐gene recurrence scoring method (Oncotype DX, Genomic Health) is used to develop personalized treatment plans for BC patients who are ER or PR‐positive, HER2‐negative, and lymph node negative by assessing the possibility of recurrence, the potential benefits of chemotherapy, and whether hormone therapy alone can be effective.35, 36